Doxorubicin-induced cardiotoxicity: Is ferroptosis the primary driver or a downstream amplifier?
DOI:
https://doi.org/10.17179/excli2026-9516Keywords:
Doxorubicin, cardiotoxicity, ferroptosis, oxidative stress, lipid peroxidationAbstract
Doxorubicin (Dox) is one of the most effective anticancer agents used to treat a wide range of solid tumors as well as hematological malignancies. However, its associated cardiotoxicity poses a major challenge for its therapeutic use. There are numerous studies exploring the underlying cellular mechanisms behind Dox-induced cardiotoxicity. Apart from the well-established apoptosis and necrosis pathways, ferroptosis is a recently identified regulated cell death pathway being studied in the context of drug-induced cardiotoxicity. Under normal physiology, cardiomyocytes maintain a highly regulated iron homeostasis, while the polyunsaturated fatty acid-rich membrane also renders it susceptible to peroxidation, a hallmark of ferroptosis. Dox-induced cardiotoxicity disrupts the coordinated control of iron metabolism, generating reactive oxygen species, propagating lipid peroxidation, and impairing mitochondrial function. Progressive structural damage and functional loss of cardiomyocytes culminate in permanent cardiac cell death. Therefore, targeting regulatory nodes of ferroptosis may be beneficial for ameliorating Dox-induced cytotoxicity. However, it is still not clear whether the ferroptotic process merely acts as an initiator or can further act as an amplifier to upregulate the downstream signaling molecules in this cell death cascade. This review offers an overview of perspectives on the ferroptotic pathway and introduces readers to a novel driver-amplifier concept.
Downloads
Published
How to Cite
License
Copyright (c) 2026 Umashanker Navik, Yogender Goswami, Nisha Sharma
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).
